Abstract Number: 1767 • ACR Convergence 2024
Endothelial Cell-Driven JAG/NOTCH Signaling in Localized Scleroderma Patients
Background/Purpose: Localized scleroderma is a rare autoimmune disease primarily affecting the skin and underlying tissue. While its exact pathogenesis remains unclear, studies suggest links to…Abstract Number: 1926 • ACR Convergence 2024
Race/ethnicity Is Associated with Disease Severity in Pediatric Patients with ANCA-associated Vasculitis Hospitalized in the United States
Background/Purpose: Race and ethnicity are societal constructs that contribute to health disparities. Small studies have found that Hispanic patients with ANCA-associated vasculitis (AAV) are more…Abstract Number: 2188 • ACR Convergence 2024
Parent Verses Patient Perspectives of Health-Related Quality of Life Among Children with Vasculitis
Background/Purpose: Vasculitis is a group of chronic, relapsing diseases that can lead to significant morbidity due to both disease and treatment, impacting patients’ health related…Abstract Number: 2206 • ACR Convergence 2024
There Is No Difference in Major Organ Involvement Andantibody Pattern Between Diffuse and Limited Subtypejuvenile Onsetsystemic Scleroderma Patients
Background/Purpose: In adult systemic sclerosis they are significant differences in clinical presentation of diffuse and limited subtype. In juvenile systemic sclerosis (jSSc) are the differences less…Abstract Number: 2623 • ACR Convergence 2024
Cardiovascular Health Is Suboptimal in Most Patients with Juvenile-Onset Lupus and Dermatomyositis: Baseline Visit Findings from the Lupus Erythematous and Dermatomyositis Stress and Cardiovascular Health Cohort Study
Background/Purpose: Juvenile lupus (JSLE) and dermatomyositis (JDM) are associated with premature cardiovascular disease (CVD). The American Heart Association (AHA) cardiovascular health (CVH) score is the…Abstract Number: 0186 • ACR Convergence 2024
Development of a Novel Dried Blood Spot Method to Improve Capacity for ANA Testing in Lower-Resource Settings
Background/Purpose: Timely diagnosis of children and young adults with rheumatologic disorders remains a global challenge especially in lower-resource settings. There is limited access to diagnostic…Abstract Number: 0397 • ACR Convergence 2024
Trends in New Use of Disease-Modifying Antirheumatic Drugs in Juvenile Idiopathic Arthritis Among Commercially Insured Children in the United States from 2001-2022
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common pediatric rheumatic disorder. An increasing array of disease-modifying antirheumatic drugs (DMARDs) have become available to treat…Abstract Number: 0832 • ACR Convergence 2024
Spatial Transcriptomic Assessment of Histologically Damaged and Unaffected Glomeruli in Class III Pediatric Lupus Nephritis Reveals Distinct Transcriptional Programs
Background/Purpose: Lupus nephritis (LN) occurs in over 50% of patients with pediatric systemic lupus erythematosus (pSLE) and results in significant morbidity due to suboptimal kidney…Abstract Number: 1265 • ACR Convergence 2024
Approach to Janus Kinase Inhibition for Juvenile Dermatomyositis Among Childhood Arthritis and Rheumatology Research Alliance (CARRA) and Paediatric Rheumatology European Society (PReS) Providers
Background/Purpose: Janus kinase inhibitors (JAKi) have been proposed as a treatment for idiopathic inflammatory myopathies to target increased interferon signaling. Predominantly retrospective reports have demonstrated…Abstract Number: 1283 • ACR Convergence 2024
Acute Transverse Myelitis in Pediatric Systemic Lupus Erythematosus
Background/Purpose: Transverse myelitis (TM) has an incidence of 1-2% in pediatric SLE and is often a feature of early disease. Most patients ( >60%) have…Abstract Number: 1769 • ACR Convergence 2024
Top Peripheral Blood Transcriptomic Gene Modules Reveal Functional Annotation and Correlation with Clinical Traits in Juvenile Dermatomyositis (JDM) and Myositis-Specific Autoantibody (MSA) Groups
Background/Purpose: Myositis-specific autoantibody (MSA) subgroups define phenotypes associated with specific clinical traits and outcomes within JDM, a clinically heterogeneous autoimmune disease. The pathogenesis of JDM…Abstract Number: 1932 • ACR Convergence 2024
Effects of Clinical Decision Support on Transition Readiness Assessment in Pediatric Rheumatology
Background/Purpose: Pediatric to adult transition is often challenging among young adults with rheumatic diseases. Structured transition programs can improve adherence to care, quality of life,…Abstract Number: 2189 • ACR Convergence 2024
Migratory Arthritis in Children: What Besides Rheumatic Fever?
Background/Purpose: Migratory Arthritis, a not uncommon presentation in pediatrics, is classically associated with rheumatic fever (RF), although can be the first presentation of other medical…Abstract Number: 2207 • ACR Convergence 2024
Improvement Across Physician and Patient Reported Outcome Measures over a 24 Months-time Period in the Juvenile Systemic Scleroderma Inception Cohort
Background/Purpose: Juvenile systemic sclerosis (jSSc) is an orphan disease with a prevalence of 3 in 1 000 000 children. The Juvenile Systemic Scleroderma Inception cohort…Abstract Number: 2624 • ACR Convergence 2024
Measuring Clinically Inactive Disease at One Year in Patients with Juvenile Dermatomyositis (JDM) in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry
Background/Purpose: While remission off medication is the goal in JDM, timely achievement of clinically inactive disease (CID) is an important interim outcome. Data from the…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 52
- Next Page »